SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX) today said that, tomorrow morning, Tuesday, February 13, the company plans to issue a news release, in which it will provide an update on the preclinical program for SILENOR™ (doxepin HCl) for the treatment of insomnia. Additionally, Somaxon management will host a conference call Tuesday morning at 9:00 a.m. Eastern Time to review the preclinical program update.
